MX2022013927A - Composiciones y metodos para tratar la epilepsia. - Google Patents

Composiciones y metodos para tratar la epilepsia.

Info

Publication number
MX2022013927A
MX2022013927A MX2022013927A MX2022013927A MX2022013927A MX 2022013927 A MX2022013927 A MX 2022013927A MX 2022013927 A MX2022013927 A MX 2022013927A MX 2022013927 A MX2022013927 A MX 2022013927A MX 2022013927 A MX2022013927 A MX 2022013927A
Authority
MX
Mexico
Prior art keywords
methods
treating epilepsy
compositions
administering
inhibitor
Prior art date
Application number
MX2022013927A
Other languages
English (en)
Spanish (es)
Inventor
Ted Yednock
Sethu Sankaranarayanan
Jeanne T Paz
Original Assignee
The J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Glads
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Glads filed Critical The J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Glads
Publication of MX2022013927A publication Critical patent/MX2022013927A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4716Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2857Seizure disorders; Epilepsy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2022013927A 2020-05-05 2021-05-05 Composiciones y metodos para tratar la epilepsia. MX2022013927A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063020245P 2020-05-05 2020-05-05
PCT/US2021/030930 WO2021242493A2 (en) 2020-05-05 2021-05-05 Compositions and methods for treating epilepsy

Publications (1)

Publication Number Publication Date
MX2022013927A true MX2022013927A (es) 2022-11-30

Family

ID=78745740

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013927A MX2022013927A (es) 2020-05-05 2021-05-05 Composiciones y metodos para tratar la epilepsia.

Country Status (8)

Country Link
US (1) US20240034775A1 (https=)
EP (1) EP4146276A4 (https=)
JP (1) JP2023524819A (https=)
CN (1) CN115996752B (https=)
AU (1) AU2021278819A1 (https=)
CA (1) CA3177879A1 (https=)
MX (1) MX2022013927A (https=)
WO (1) WO2021242493A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3019240T3 (da) 2013-07-09 2024-06-03 Annexon Inc Anti-komplementfaktor C1Q antistoffer og anvendelser deraf
US12486322B2 (en) * 2021-12-13 2025-12-02 Annexon, Inc. Anti-complement factor C1q antibodies with single binding arms and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2914291T3 (da) * 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
DK3019240T3 (da) * 2013-07-09 2024-06-03 Annexon Inc Anti-komplementfaktor C1Q antistoffer og anvendelser deraf
SI3215527T1 (sl) * 2014-11-05 2025-04-30 Annexon, Inc. Humanizirana protitelesa proti komplementnemu faktorju C1q in njihova uporaba
US10508151B2 (en) * 2014-11-19 2019-12-17 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
KR20250053203A (ko) * 2015-07-24 2025-04-21 글리크닉 인코포레이티드 향상된 상보체 결합을 갖는 규칙적으로 다형체화된 면역글로불린 fc 조성물을 생성하기 위한 인간 단백질 단편의 융합 단백질
EP3380518B1 (en) * 2015-11-24 2026-03-25 Annexon, Inc. Anti-complement factor c1q fab fragments and uses thereof
CA3023667A1 (en) * 2016-05-09 2017-11-16 Annexon, Inc. Compositions and methods for treating spinal muscular atrophy
SG11201900123TA (en) * 2016-07-19 2019-02-27 Annexon Inc Compositions and methods for treating frontotemporal dementia
CN119080931A (zh) * 2018-06-04 2024-12-06 马萨诸塞州渤健公司 具有降低的效应功能的抗vla-4抗体
JP7499760B2 (ja) * 2018-11-02 2024-06-14 アネクソン,インコーポレーテッド 脳損傷を治療するための組成物及び方法
WO2020124013A1 (en) * 2018-12-13 2020-06-18 Gryphon Bio, Inc. Combinatorial temporal biomarkers and precision medicines with detection and treatment methods for use in neuro injury, neuro disease, and neuro repair

Also Published As

Publication number Publication date
JP2023524819A (ja) 2023-06-13
EP4146276A4 (en) 2024-08-14
CA3177879A1 (en) 2021-12-02
EP4146276A2 (en) 2023-03-15
WO2021242493A2 (en) 2021-12-02
WO2021242493A3 (en) 2022-06-09
US20240034775A1 (en) 2024-02-01
AU2021278819A1 (en) 2022-11-24
CN115996752B (zh) 2025-04-01
CN115996752A (zh) 2023-04-21

Similar Documents

Publication Publication Date Title
MX2024000271A (es) Inhibidor de shp2 y uso del mismo.
MY208545A (en) Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith
PH12020551995A1 (en) Modulator of apol1 expression
MY206796A (en) Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma
PH12021551463A1 (en) Modulators of hsd17b13 expression
PH12019502174A1 (en) Modulators of pcsk9 expression
MY197758A (en) Methods for treating conditions associated with masp-2 dependent complement activation
NI202100018A (es) Moduladores de la expresión de pnpla3
PH12022550130A1 (en) Enzyme inhibitors
MX2021004819A (es) Composiciones y metodos para tratar lesiones cerebrales.
PH12022550491A1 (en) Perk inhibiting pyrrolopyrimidine compounds
MX2022013927A (es) Composiciones y metodos para tratar la epilepsia.
WO2022020353A3 (en) Methods and compositions for treatment and prevention of coronavirus infection
PH12022550497A1 (en) Perk inhibiting compounds
PH12022550045A1 (en) Plasma kallikrein inhibitors
MX2024010804A (es) Butirato alimenticio para tratar o prevenir un trastorno alergico.
PH12021552866A1 (en) Compositions and methods for treating cancer
PH12022550118A1 (en) Enzyme inhibitors
MX2024008831A (es) Terapia combinada para carcinoma hepatocelular.
MX2021008918A (es) Moduladores de expresion yap1.
ZA202103914B (en) Cxcr7 inhibitors for the treatment of cancer
MX2022008532A (es) Inhibidores de hidrocarburo de arilo (ahr) y usos de estos.
PH12021552499A1 (en) Methods for the treatment of beta-thalassemia
MX2021009535A (es) Uso de composiciones tópicas de inhibidores de braf para el tratamiento de la dermatitis por radiación.
WO2019173478A3 (en) Combination of depletes tregs and a checkpoint inhibitor